Related Experiment Video
Updated: Aug 14, 2026
Viability Assays for Cells in Culture
Published on: January 20, 2014
Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in
Silvana Alfei1, Cinzia Domenicotti2,3, Sara Tirendi2,4
1Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy.
Abstract:
High-risk neuroblastoma (HR-NB) remains a major clinical challenge due to the emergence of therapy resistance. In this study, the anticancer effects of seven previously synthesized betulin (BET), betulinic acid (BA) and ursolic acid (UA) derivatives (1-7) and of their natural precursors BET, BA and UA (8-10) were investigated in HTLA NB cells, selected as the experimental model by MTT assay, to find a possible solution to drugs that have lost their effect. Dynamic light scattering (DLS) analysis showed that amphiphilic compounds 1 and 4-7 form nanovesicles (240-448 nm) in water, while all compounds have high positive ζ-potential (ζ-p, +28.5-+83.1 mV), supporting favourable membrane interaction and cellular uptake. Cytotoxic experiment results and related IC50 values were expressed as the mean ± SD of four independent experiments run in triplicate. Most derivatives exhibited a cytotoxic activity higher than that of their natural precursors and outperformed etoposide; they were particularly effective against the multidrug resistant (MDR) HTLA ER cells. Among them, the ursolic acid (UA) derivative 7 emerged as the most active compound, displaying sub-micromolar to low micromolar IC50 values and markedly improving the activity of native UA. Functional studies revealed that it induces complete suppression of clonogenic growth at low micromolar concentrations in both HTLA ER and parental HTLA 230 NB cells. In addition, a concentration-dependent downregulation of Akt, p-Akt, BMI1 and PARP, was observed consistently with a marked suppression of survival pathways and loss of cellular homeostasis. Collectively, our experiments, which need further direct investigation to confirm subsequent assumption, could suggest that compound 7 could kill cancer cells via a non-apoptotic, bioenergetic collapse mechanism. All of these findings suggest compound 7 as a promising mitochondria-targeted lead candidate and support amphiphilic triterpenoid derivatives as attractive platforms for overcoming multidrug resistance in high-risk NB.
Insights
Ursolic acid derivative 7 shows potent anticancer effects against high-risk neuroblastoma (HR-NB), overcoming multidrug resistance. This compound may offer a new therapeutic strategy by targeting mitochondria and causing bioenergetic collapse.
Area of Science:
- Natural Product Chemistry
- Cancer Biology
- Drug Discovery
Background:
- High-risk neuroblastoma (HR-NB) presents a significant clinical challenge due to acquired therapy resistance.
- Existing treatments for HR-NB often face limitations from multidrug resistance (MDR).
Purpose of the Study:
- To evaluate the anticancer potential of betulin, betulinic acid, and ursolic acid derivatives against HR-NB cells.
- To identify novel compounds capable of overcoming MDR in neuroblastoma.
Main Methods:
- MTT assay for cell viability screening.
- Dynamic Light Scattering (DLS) for nanovesicle formation and zeta potential analysis.
- Cytotoxicity assays (IC50 determination) and functional studies (clonogenic growth, Western blotting for signaling pathway analysis).
Main Results:
- Amphiphilic derivatives formed nanovesicles with favorable membrane interaction properties.
- Most derivatives exhibited superior cytotoxic activity compared to natural precursors and etoposide, particularly against MDR cells.
- Ursolic acid derivative 7 demonstrated significant potency, suppressed clonogenic growth, and downregulated key survival proteins (Akt, p-Akt, BMI1, PARP).
Conclusions:
- Ursolic acid derivative 7 is a promising lead compound for HR-NB, potentially acting via a non-apoptotic, bioenergetic collapse mechanism.
- Amphiphilic triterpenoid derivatives represent a viable platform for developing new therapies against MDR in HR-NB.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...